A study in the Journal of the American Medical Association found that people who took popular GLP-1 drugs for weight loss, particularly Novo Nordisk’s Ozempic, or semaglutide, and Victoza, or liraglutide, were more likely to suffer from pancreatitis, stomach paralysis and bowel obstruction than those who took another kind of weight-loss drug called Contrave, or bupropion-naltrexone. “Although the incidence of these adverse events are relatively rare, affecting only about 1% of patients, with millions taking these medications, thousands of people are likely to be affected by these adverse events," lead researcher Dr. Mohit Sodhi said.
Full Story: NBC News (10/5), HealthDay News (10/5)